Association of PD-L1 Expression with Tumor-Infiltrating Immune Cells and Mutation Burden in High-Grade Neuroendocrine Carcinoma of the Lung
Hye Sook Kim(Myongji Hospital), Ji‐Youn Han(National Cancer Centre Japan)
Cited by 82
Related Papers
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
|The Lancet Oncology|2020|413
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous <i>EGFR</i> -Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial
|Journal of Clinical Oncology|2024|131
Hypoxia-inducible Factor 1α and Antiangiogenic Activity of Farnesyltransferase Inhibitor SCH66336 in Human Aerodigestive Tract Cancer
|JNCI Journal of the National Cancer Institute|2005|97
Integrative analysis of risk factors for immune-related adverse events of checkpoint blockade therapy in cancer
|Nature Cancer|2023|46
A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer
|Clinical Lung Cancer|2021|39